Literature DB >> 21249647

Multiple risk factor interventions for primary prevention of coronary heart disease.

Shah Ebrahim1, Fiona Taylor, Kirsten Ward, Andrew Beswick, Margaret Burke, George Davey Smith.   

Abstract

BACKGROUND: Multiple risk factor interventions using counselling and educational methods assumed to be efficacious and cost-effective in reducing coronary heart disease (CHD) mortality and morbidity and that they should be expanded. Trials examining risk factor changes have cast doubt on the effectiveness of these interventions.
OBJECTIVES: To assess the effects of multiple risk factor interventions for reducing total mortality, fatal and non-fatal events from CHD and cardiovascular risk factors among adults assumed to be without prior clinical evidence CHD.. SEARCH STRATEGY: We updated the original search BY SEARCHING CENTRAL (2006, Issue 2), MEDLINE (2000 to June 2006) and EMBASE (1998 to June 2006), and checking bibliographies. SELECTION CRITERIA: Randomised controlled trials of more than six months duration using counselling or education to modify more than one cardiovascular risk factor in adults from general populations, occupational groups or specific risk factors (i.e. diabetes, hypertension, hyperlipidaemia, obesity). DATA COLLECTION AND ANALYSIS: Two authors extracted data independently. We expressed categorical variables as odds ratios (OR) with 95% confidence intervals (CI). Where studies published subsequent follow-up data on mortality and event rates, we updated these data. MAIN
RESULTS: We found 55 trials (163,471 participants) with a median duration of 12 month follow up. Fourteen trials (139,256 participants) with reported clinical event endpoints, the pooled ORs for total and CHD mortality were 1.00 (95% CI 0.96 to 1.05) and 0.99 (95% CI 0.92 to 1.07), respectively. Total mortality and combined fatal and non-fatal cardiovascular events showed benefits from intervention when confined to trials involving people with hypertension (16 trials) and diabetes (5 trials): OR 0.78 (95% CI 0.68 to 0.89) and OR 0.71 (95% CI 0.61 to 0.83), respectively. Net changes (weighted mean differences) in systolic and diastolic blood pressure (53 trials) and blood cholesterol (50 trials) were -2.71 mmHg (95% CI -3.49 to -1.93), -2.13 mmHg (95% CI -2.67 to -1.58 ) and -0.24 mmol/l (95% CI -0.32 to -0.16), respectively. The OR for reduction in smoking prevalence (20 trials) was 0.87 (95% CI 0.75 to 1.00). Marked heterogeneity (I(2) > 85%) for all risk factor analyses was not explained by co-morbidities, allocation concealment, use of antihypertensive or cholesterol-lowering drugs, or by age of trial. AUTHORS'
CONCLUSIONS: Interventions using counselling and education aimed at behaviour change do not reduce total or CHD mortality or clinical events in general populations but may be effective in reducing mortality in high-risk hypertensive and diabetic populations. Risk factor declines were modest but owing to marked unexplained heterogeneity between trials, the pooled estimates are of dubious validity. Evidence suggests that health promotion interventions have limited use in general populations.

Entities:  

Mesh:

Year:  2011        PMID: 21249647     DOI: 10.1002/14651858.CD001561.pub3

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  137 in total

1.  Randomized controlled trial on the long-term efficacy of a multifaceted, interdisciplinary lifestyle intervention in reducing cardiovascular risk and improving lifestyle in patients at risk of cardiovascular disease.

Authors:  Lysanne Goyer; Robert Dufour; Caroline Janelle; Chantal Blais; Christine L'Abbé; Emilie Raymond; Jacques de Champlain; Pierre Larochelle
Journal:  J Behav Med       Date:  2012-03-09

2.  The Fremantle Primary Prevention Study: a multicentre randomised trial of absolute cardiovascular risk reduction.

Authors:  Benjamin Philpot; Kevin McNamara; James A Dunbar
Journal:  Br J Gen Pract       Date:  2012-04       Impact factor: 5.386

Review 3.  Cardiovascular disease risk factors: a childhood perspective.

Authors:  Pradeep A Praveen; Ambuj Roy; Dorairaj Prabhakaran
Journal:  Indian J Pediatr       Date:  2012-05-27       Impact factor: 1.967

Review 4.  Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: An Overview of Systematic Reviews.

Authors:  Kunal N Karmali; Donald M Lloyd-Jones; Mark A Berendsen; David C Goff; Darshak M Sanghavi; Nina C Brown; Liliya Korenovska; Mark D Huffman
Journal:  JAMA Cardiol       Date:  2016-06-01       Impact factor: 14.676

5.  The Effects of Two Influential Early Childhood Interventions on Health and Healthy Behaviour.

Authors:  Gabriella Conti; James Heckman; Rodrigo Pinto
Journal:  Econ J (London)       Date:  2016-12-07

Review 6.  Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases.

Authors:  Ehete Bahiru; Angharad N de Cates; Matthew Rb Farr; Morag C Jarvis; Mohan Palla; Karen Rees; Shah Ebrahim; Mark D Huffman
Journal:  Cochrane Database Syst Rev       Date:  2017-03-06

Review 7.  Natriuretic peptide-guided treatment for the prevention of cardiovascular events in patients without heart failure.

Authors:  Claire Sweeney; Fiona Ryan; Mark Ledwidge; Cristin Ryan; Ken McDonald; Chris Watson; Rebabonye B Pharithi; Joe Gallagher
Journal:  Cochrane Database Syst Rev       Date:  2019-10-15

Review 8.  Novel treatments for cardiovascular disease prevention.

Authors:  Mark D Huffman; Deepak Bhatnagar
Journal:  Cardiovasc Ther       Date:  2011-05-31       Impact factor: 3.023

9.  Increased Mortality Despite Successful Multifactorial Cardiovascular Risk Reduction in Healthy Men: 40-Year Follow-Up of the Helsinki Businessmen Study Intervention Trial.

Authors:  T E Strandberg; K Räikkönen; V Salomaa; A Strandberg; H Kautiainen; M Kivimäki; K Pitkälä; J Huttunen
Journal:  J Nutr Health Aging       Date:  2018       Impact factor: 4.075

Review 10.  Outpatient diabetes clinical decision support: current status and future directions.

Authors:  P J O'Connor; J M Sperl-Hillen; C J Fazio; B M Averbeck; B H Rank; K L Margolis
Journal:  Diabet Med       Date:  2016-06       Impact factor: 4.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.